Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick M Howard

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerFrederick M Howard, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceNgoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerFrederick M Howard, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceNgoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Pageof 6